Trilateral retinoblastoma: potentially curable with intensive chemotherapy. 2010

Ira J Dunkel, and Rima F Jubran, and Sri Gururangan, and Guillermo L Chantada, and Jonathan L Finlay, and Stewart Goldman, and Yasmin Khakoo, and Joan M O'Brien, and Manuela Orjuela, and Carlos Rodriguez-Galindo, and Mark M Souweidane, and David H Abramson
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. dunkeli@mskcc.org

BACKGROUND Trilateral retinoblastoma has been lethal in virtually all cases previously reported. We describe a series of 13 patients treated with intensive chemotherapy, defined as the intention to include high-dose chemotherapy with autologous hematopoietic stem cell rescue. METHODS Induction chemotherapy generally included vincristine, cisplatin or carboplatin, cyclophosphamide, and etoposide. Hematopoietic stem cells typically were harvested after the first or second cycle of induction chemotherapy, usually from peripheral blood. High-dose chemotherapy regimens were thiotepa-based (n = 7) or melphalan and cyclophosphamide (n = 3). RESULTS Trilateral sites were pineal (n = 11) and suprasellar (n = 2); 7 patients had localized (M-0) disease and six had leptomeningeal dissemination (M-1+). Five patients had trilateral retinoblastoma at original diagnosis of intra-ocular retinoblastoma; eight later developed trilateral disease at a median of 35 months (range 3-60 months) following diagnosis of intra-ocular retinoblastoma. One patient died of toxicity (septicemia and multi-organ system failure) during induction and three developed disease progression prior to high-dose chemotherapy. Nine patients received high-dose chemotherapy at a median of 5 months (range 4-9) post-diagnosis of trilateral disease. Five patients survive event-free at a median of 77 months (range 36-104 months) and never received external beam radiation therapy. Four of seven patients with M-0 disease survive event-free versus only one of six patients with M-1+ disease. CONCLUSIONS Intensive chemotherapy is potentially curative for some patients with trilateral retinoblastoma, especially those with M-0 disease.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008577 Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord. Intracranial Meningeal Neoplasms,Spinal Meningeal Neoplasms,Benign Meningeal Neoplasms,Leptomeningeal Neoplasms,Malignant Meningeal Neoplasms,Meningeal Cancer,Meningeal Neoplasms, Benign,Meningeal Neoplasms, Intracranial,Meningeal Neoplasms, Malignant,Meningeal Tumors,Neoplasms, Leptomeningeal,Neoplasms, Meningeal,Benign Meningeal Neoplasm,Cancer, Meningeal,Cancers, Meningeal,Intracranial Meningeal Neoplasm,Leptomeningeal Neoplasm,Malignant Meningeal Neoplasm,Meningeal Cancers,Meningeal Neoplasm,Meningeal Neoplasm, Benign,Meningeal Neoplasm, Intracranial,Meningeal Neoplasm, Malignant,Meningeal Neoplasm, Spinal,Meningeal Neoplasms, Spinal,Meningeal Tumor,Neoplasm, Benign Meningeal,Neoplasm, Intracranial Meningeal,Neoplasm, Leptomeningeal,Neoplasm, Malignant Meningeal,Neoplasm, Meningeal,Neoplasm, Spinal Meningeal,Neoplasms, Benign Meningeal,Neoplasms, Intracranial Meningeal,Neoplasms, Malignant Meningeal,Neoplasms, Spinal Meningeal,Spinal Meningeal Neoplasm,Tumor, Meningeal,Tumors, Meningeal
D010870 Pineal Gland A light-sensitive neuroendocrine organ attached to the roof of the THIRD VENTRICLE of the brain. The pineal gland secretes MELATONIN, other BIOGENIC AMINES and NEUROPEPTIDES. Epiphysis Cerebri,Pineal Body,Corpus Pineale,Gland, Pineal,Pineal Bodies,Pineal Glands
D010871 Pinealoma Neoplasms which originate from pineal parenchymal cells that tend to enlarge the gland and be locally invasive. The two major forms are pineocytoma and the more malignant pineoblastoma. Pineocytomas have moderate cellularity and tend to form rosette patterns. Pineoblastomas are highly cellular tumors containing small, poorly differentiated cells. These tumors occasionally seed the neuroaxis or cause obstructive HYDROCEPHALUS or Parinaud's syndrome. GERMINOMA; CARCINOMA, EMBRYONAL; GLIOMA; and other neoplasms may arise in the pineal region with germinoma being the most common pineal region tumor. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2064; Adams et al., Principles of Neurology, 6th ed, p670) Neoplasms, Pineal,Pineal Neoplasms,Pinealocytoma,Pineoblastoma,Pineocytoma,Mixed Pineocytoma-Pineoblastoma,Pineal Gland Tumor,Pineal Parenchymal Tumors,Pineal Tumors,Mixed Pineocytoma Pineoblastoma,Mixed Pineocytoma-Pineoblastomas,Neoplasm, Pineal,Pineal Gland Tumors,Pineal Neoplasm,Pineal Parenchymal Tumor,Pineal Tumor,Pinealocytomas,Pinealomas,Pineoblastomas,Pineocytoma-Pineoblastoma, Mixed,Pineocytoma-Pineoblastomas, Mixed,Pineocytomas,Tumor, Pineal,Tumor, Pineal Gland,Tumor, Pineal Parenchymal,Tumors, Pineal,Tumors, Pineal Gland,Tumors, Pineal Parenchymal
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide

Related Publications

Ira J Dunkel, and Rima F Jubran, and Sri Gururangan, and Guillermo L Chantada, and Jonathan L Finlay, and Stewart Goldman, and Yasmin Khakoo, and Joan M O'Brien, and Manuela Orjuela, and Carlos Rodriguez-Galindo, and Mark M Souweidane, and David H Abramson
March 2011, Archives of ophthalmology (Chicago, Ill. : 1960),
Ira J Dunkel, and Rima F Jubran, and Sri Gururangan, and Guillermo L Chantada, and Jonathan L Finlay, and Stewart Goldman, and Yasmin Khakoo, and Joan M O'Brien, and Manuela Orjuela, and Carlos Rodriguez-Galindo, and Mark M Souweidane, and David H Abramson
February 1984, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie,
Ira J Dunkel, and Rima F Jubran, and Sri Gururangan, and Guillermo L Chantada, and Jonathan L Finlay, and Stewart Goldman, and Yasmin Khakoo, and Joan M O'Brien, and Manuela Orjuela, and Carlos Rodriguez-Galindo, and Mark M Souweidane, and David H Abramson
January 1985, Bulletin des societes d'ophtalmologie de France,
Ira J Dunkel, and Rima F Jubran, and Sri Gururangan, and Guillermo L Chantada, and Jonathan L Finlay, and Stewart Goldman, and Yasmin Khakoo, and Joan M O'Brien, and Manuela Orjuela, and Carlos Rodriguez-Galindo, and Mark M Souweidane, and David H Abramson
January 1999, Acta neurochirurgica,
Ira J Dunkel, and Rima F Jubran, and Sri Gururangan, and Guillermo L Chantada, and Jonathan L Finlay, and Stewart Goldman, and Yasmin Khakoo, and Joan M O'Brien, and Manuela Orjuela, and Carlos Rodriguez-Galindo, and Mark M Souweidane, and David H Abramson
June 2011, The Medical journal of Malaysia,
Ira J Dunkel, and Rima F Jubran, and Sri Gururangan, and Guillermo L Chantada, and Jonathan L Finlay, and Stewart Goldman, and Yasmin Khakoo, and Joan M O'Brien, and Manuela Orjuela, and Carlos Rodriguez-Galindo, and Mark M Souweidane, and David H Abramson
January 1986, Medical and pediatric oncology,
Ira J Dunkel, and Rima F Jubran, and Sri Gururangan, and Guillermo L Chantada, and Jonathan L Finlay, and Stewart Goldman, and Yasmin Khakoo, and Joan M O'Brien, and Manuela Orjuela, and Carlos Rodriguez-Galindo, and Mark M Souweidane, and David H Abramson
July 1991, AJR. American journal of roentgenology,
Ira J Dunkel, and Rima F Jubran, and Sri Gururangan, and Guillermo L Chantada, and Jonathan L Finlay, and Stewart Goldman, and Yasmin Khakoo, and Joan M O'Brien, and Manuela Orjuela, and Carlos Rodriguez-Galindo, and Mark M Souweidane, and David H Abramson
January 1983, Journal of pediatric ophthalmology and strabismus,
Ira J Dunkel, and Rima F Jubran, and Sri Gururangan, and Guillermo L Chantada, and Jonathan L Finlay, and Stewart Goldman, and Yasmin Khakoo, and Joan M O'Brien, and Manuela Orjuela, and Carlos Rodriguez-Galindo, and Mark M Souweidane, and David H Abramson
January 2006, Pediatric radiology,
Ira J Dunkel, and Rima F Jubran, and Sri Gururangan, and Guillermo L Chantada, and Jonathan L Finlay, and Stewart Goldman, and Yasmin Khakoo, and Joan M O'Brien, and Manuela Orjuela, and Carlos Rodriguez-Galindo, and Mark M Souweidane, and David H Abramson
January 1992, Metabolic, pediatric, and systemic ophthalmology (New York, N.Y. : 1985),
Copied contents to your clipboard!